


Form Approved OMB No. 0920-0666 Exp. Date: 12/31/22 www.cdc.gov/nhsn

## Hemovigilance Module Adverse Reaction Transfusion Associated Graft vs. Host Disease

*Required for saving					
*Facility ID#: NHSN Adv	verse Reaction #:				
Patient Information					
*Patient ID:	*Gender: M F Other *Date of Birth:I				
Sex at Birth: ☐ M ☐ F ☐ Unknown	Gender Identity (Specify):				
Social Security #:	Secondary ID: Medicare #:				
Last Name:	First Name: Middle Name:				
Ethnicity Hispanic or Latino	Not Hispanic or Not Latino				
Race American Indian/Alask Native Hawaiian/Other					
*Blood Group: A- A+ B  Transitional ABO / F	B+ AB- AB+ O- O+ Blood type not done Transitional ABO / Rh - Rh				
Group A/Transitional Group Rh					
Patient Medical History					
List the patient's admitting diagnosi	is. (Use ICD-10 Diagnostic codes/descriptions)				
Code:	Description:				
	Description:				
	Description:				
List the patient's underlying indicati	ion for transfusion. (Use ICD-10 Diagnostic codes/descriptions)				
Code: [	Description:				
	Description:				
	Description:				
List the patient's comorbid conditions at the time of the transfusion related to the adverse reaction. (Use ICD-10 Diagnostic codes/descriptions)					
Code:	Description:				
Code:	Description:				
	Description:				
Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).					
reviewing instructions, searching existing data collection of information. An agency may no unless it displays a currently valid OMB cont	information is estimated to average 20 minutes per response, including the time for the sources, gathering and maintaining the data needed, and completing and reviewing the object conduct or sponsor, and a person is not required to respond to a collection of information trol number. Send comments regarding this burden estimate or any other aspect of this ons for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-666).				









	edical procedure including past procedures and procedures to be thospital or outpatient stay. (Use ICD-10 Procedure  NONE
Code:	Description:
Code:	Description:
Code:	Description:
Additional Information	
Transfusion History	
Has the patient received a p	revious transfusion? YES NO UNKNOWN
Blood Product:	WB RBC Platelet Plasma Cryoprecipitate Granulocyte
Date of Transfusion:	// UNKNOWN
Was the patient's adverse	reaction transfusion-related? YES NO
If yes, provide information	about the transfusion adverse reaction.
Type of transfusion advers	se reaction: Allergic AHTR DHTR DSTR FNHTR
HTR TTI	PTP TACO TAD TA-GVHD TRALI UNKNOWN
OTHER Specify	/
Reaction Details	
*Date reaction occurred:/	/ *Time reaction occurred:: Time unknown
*Facility location where patie	nt was transfused:
Is this reaction associated with	an incident? Yes No If Yes, Incident #:
Investigation Results	
	graft vs. host disease (TA-GVHD)
	graft vs. host disease (TA-GVHD)
* Transfusion associated  *Case Definition	graft vs. host disease (TA-GVHD)  adiated blood product(s) in the two months preceding the reaction?  Yes No
* Transfusion associated  *Case Definition  Did patient receive non-irra	
* Transfusion associated  *Case Definition  Did patient receive non-irra	adiated blood product(s) in the two months preceding the reaction?
* Transfusion associated  *Case Definition  Did patient receive non-irra  Check all that occurred with Clinical syndrome	adiated blood product(s) in the two months preceding the reaction?
* Transfusion associated  *Case Definition  Did patient receive non-irra  Check all that occurred with Clinical syndrome  Clinical syndrome	adiated blood product(s) in the two months preceding the reaction? Yes No ithin 2 days to 6 weeks after cessation of transfusion:
* Transfusion associated  *Case Definition  Did patient receive non-irra  Check all that occurred with Clinical syndrome  Clinical syndrome  Liver dysfuncti  Characteristic	adiated blood product(s) in the two months preceding the reaction? Yes No  ithin 2 days to 6 weeks after cessation of transfusion:  characteristics: Diarrhea Fever Hepatomegaly Pancytopenia on (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia rash: erythematous, maculopapular eruption centrally that spreads to extremities and
* Transfusion associated  *Case Definition  Did patient receive non-irra  Check all that occurred with Clinical syndrome  Clinical syndrome  Liver dysfunction  Characteristic may, in severe case	adiated blood product(s) in the two months preceding the reaction? Yes No  ithin 2 days to 6 weeks after cessation of transfusion:  characteristics: Diarrhea Fever Hepatomegaly Pancytopenia on (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia
*Transfusion associated  *Case Definition Did patient receive non-irra  Check all that occurred with Clinical syndrome Clinical syndrome Liver dysfuncti Characteristic may, in severe case  Check all that apply:	adiated blood product(s) in the two months preceding the reaction? Yes No ithin 2 days to 6 weeks after cessation of transfusion:  characteristics: Diarrhea Fever Hepatomegaly Pancytopenia on (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia rash: erythematous, maculopapular eruption centrally that spreads to extremities and ses, progress to generalized erythroderma and hemorrhagic bullous formation.
* Transfusion associated  *Case Definition  Did patient receive non-irra  Check all that occurred with the common of the common	adiated blood product(s) in the two months preceding the reaction? Yes No ithin 2 days to 6 weeks after cessation of transfusion:  characteristics: Diarrhea Fever Hepatomegaly Pancytopenia on (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia rash: erythematous, maculopapular eruption centrally that spreads to extremities and ses, progress to generalized erythroderma and hemorrhagic bullous formation.
* Transfusion associated (*Case Definition Did patient receive non-irration Check all that occurred with Clinical syndrome Clinical syndrome Liver dysfunction Characteristic may, in severe cast Check all that apply:    Characteristic histology Biopsy negative or not continued by the continued b	adiated blood product(s) in the two months preceding the reaction? Yes No ithin 2 days to 6 weeks after cessation of transfusion:  characteristics: Diarrhea Fever Hepatomegaly Pancytopenia on (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia rash: erythematous, maculopapular eruption centrally that spreads to extremities and ses, progress to generalized erythroderma and hemorrhagic bullous formation.  egical appearance of skin or liver biopsy. ot done.
* Transfusion associated  *Case Definition  Did patient receive non-irra  Check all that occurred with a Clinical syndrome  Clinical syndrome  Clinical syndrome  Liver dysfuncti  Characteristic may, in severe case  Check all that apply:  Characteristic histology is proposed in the company of the company o	adiated blood product(s) in the two months preceding the reaction? Yes No  ithin 2 days to 6 weeks after cessation of transfusion:  characteristics: Diarrhea Fever Hepatomegaly Pancytopenia on (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia rash: erythematous, maculopapular eruption centrally that spreads to extremities and ses, progress to generalized erythroderma and hemorrhagic bullous formation.  ogical appearance of skin or liver biopsy. ot done.  (check all that apply)
* Transfusion associated  *Case Definition  Did patient receive non-irra  Check all that occurred with Clinical syndrome  Clinical syndrome  Clinical syndrome  Liver dysfuncti  Characteristic may, in severe case  Check all that apply:  Characteristic histolo  Biopsy negative or not other signs and symptoms:  Generalized:	adiated blood product(s) in the two months preceding the reaction? Yes No ithin 2 days to 6 weeks after cessation of transfusion:  characteristics: Diarrhea Fever Hepatomegaly Pancytopenia on (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia rash: erythematous, maculopapular eruption centrally that spreads to extremities and ses, progress to generalized erythroderma and hemorrhagic bullous formation.  gical appearance of skin or liver biopsy. ot done.  (check all that apply) Chills/rigors Nausea/vomiting
* Transfusion associated  *Case Definition  Did patient receive non-irra  Check all that occurred with a Clinical syndrome  Clinical syndrome  Clinical syndrome  Liver dysfuncti  Characteristic may, in severe case  Check all that apply:  Characteristic histology is proposed in the company of the company o	adiated blood product(s) in the two months preceding the reaction? Yes No  ithin 2 days to 6 weeks after cessation of transfusion:  characteristics: Diarrhea Fever Hepatomegaly Pancytopenia on (i.e., elevated ALT, AST, Alkaline phosphatase, and bilirubin) Marrow aplasia rash: erythematous, maculopapular eruption centrally that spreads to extremities and ses, progress to generalized erythroderma and hemorrhagic bullous formation.  ogical appearance of skin or liver biopsy. ot done.  (check all that apply)



Form Approved OMB No. 0920-0666 Exp. Date: 12/31/22 www.cdc.gov/nhsn

Hemolysis/Hemorrhage:	Disseminated intravascular coagulation Hemoglobinemia						
	Positive antibody	screen					
Pain:	Abdominal pain	Back pain	Flank pain	Infusion site pain			
Renal:	Hematuria	Hemoglobinuria	a Oliguria				
Respiratory:	Bronchospasm	Bronchospasm Cough Shortness of breath					
Other: (specify)							
*Severity							
Did the patient receive or	experience any of the f	following?					
No treatment requi	red	Symptomatic tr	eatment only				
Hospitalization, inlo	cuding prolonged hospi	italization	Life-threatening	g reaction			
Disability and/or in	capacitation	Congenital ano	maly or birth defect(s	s) of the fetus			
Other medically important conditions Death Unknown or not stated							
*Imputability							
Which best describes the	relationship between th	e transfusion and th	e reaction?				
No other alternative	•						
	ses are present (e.g., s	tem cell transplantat	ion).				
	ions are more likely (e.	•	,				
	n favor of a cause othe	•	•	nnot be excluded.			
	evidence beyond reaso						
	ween the adverse reac						
Did the transfusion occur a		YES NO	ion is analown of floo	t stated.			
WBC chimerism: WBC chimerism present WBC chimerism not present or not done							
Module-generated Design	nations						
NOTE: Designations for case of application based on response	definition, severity, and			d in the NHSN			
		•	YES	NO			
*Do you agree with the <u>case definition</u> designation?  ^Please indicate your designation			YES				
			VEC	NO			
*Do you agree with the <u>severity</u> designation?  ^Please indicate your designation							
*Do you agree with the <u>i</u>	<u>mputability</u> designati	on?	YES	NO			
^Please indicate your des	ignation						
Patient Treatment							
Did the patient receive treat	ment for the transfusio	n reaction?	YES NO	UNKNOWN			
If yes, select treatment(s):							
Medication (Select the type of medication)							
Antipyretics Antihistamines Inotropes/Vasopressors Bronchodilator Diuretics							
Intravenous							
Immunoglobulin							
Antithymocyte globulin Cyclosporin Other							



Form Approved OMB No. 0920-0666 Exp. Date: 12/31/22 www.cdc.gov/nhsn

Volu	Volume resuscitation (Intravenous colloids or crystalloids)									
Respiratory support (Select the type of support)										
Renal replacement therapy (Select the type of therapy)  Hemodialysis Peritoneal Continuous Veno-Venous Hemofiltration										
Phle	ebotomy									
Other Specify:										
Outcome										
*Outcome: Death Major or long-term sequelae Minor or no sequelae Not determined										
Date of		/								
	ecipient died, relation Definite  Probabl	. —	_	Doubtful	Ruled Out	Not determin	and			
	of death:	e Dossib	ie [		Ruled Out	Not determin	ieu			
	autopsy performed?	Yes	No	)						
*Was a partic reaction?	cular unit implicated	d in (i.e., respo	nsibl	e for) the a	dverse	Yes No	N/A			
Transfusion Start and End Date/Time	*Component code (check system used)	Amount transfused at reaction onset	(Requ	number lired for on and	*Unit expiration Date/Time	*Blood group	Implicat ed Unit?			
^IMPLICATED				.,		,	1011111			
1 1	ISBT-128									
:	Codabar	Entire unit			, ,	A- A+ B-				
·		Partial unit					Y			
//		mL				B+ AB- AB+				
<u> </u>					::	O- O+ N/A				
//	ISBT-128					h. h. h <sub>-</sub>				
:	Codabar	Entire unit Partial unit				A- A+ B-	N			
		mL				B+ AB- AB+				
:					:	O- O+ N/A				
Custom Field	ds									
Label				Label						
Comments										



